Medicare Enrolled
Dr. Rimas Lukas, M.D.
Neurology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lukas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lukas?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lukas
Dr. Rimas Lukas is a neurology specialist in Chicago, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Lukas performed 63,904 Medicare services across 1,416 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lukas received a total of $165,348 from 18 pharmaceutical and/or device companies across 169 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lukas is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 0% volume in IL
$165,348 industry payments
Medicare Practice Summary
Medicare Utilization ↗63,904
Medicare services
Top 0% in IL for neurology
1,416
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,363 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
13,320 | $38 | $170 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
9,000 | $1 | $5 |
| Nivolumab injection (Opdivo) | 7,380 | $24 | $97 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
6,500 | $2 | $14 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,550 | $0 | $7 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
4,610 | $36 | $134 |
| Pembrolizumab injection (Keytruda) | 3,400 | $43 | $171 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
2,662 | $23 | $194 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
2,323 | $4 | $174 |
| Denosumab injection (Prolia/Xgeva) | 2,100 | $18 | $58 |
| Injection, atropine sulfate, 0.01 mg | 1,240 | $0 | $1 |
| Pemetrexed injection, 10 mg Administration of a 10 mg dose of pemetrexed medication via injection. |
1,183 | $15 | $226 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
870 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 820 | $1 | $76 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
433 | $2 | $8 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
359 | $4 | $10 |
| Injection, irinotecan, 20 mg | 278 | $2 | $45 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
226 | $13 | $142 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
225 | $108 | $940 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
180 | $80 | $821 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
177 | $17 | $129 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
159 | $60 | $326 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
135 | $139 | $434 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
117 | $24 | $203 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
113 | $53 | $410 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
82 | $12 | $88 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
63 | $23 | $215 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
57 | $93 | $323 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
52 | $97 | $250 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
48 | $204 | $1,618 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
46 | $54 | $464 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
45 | $66 | $217 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
39 | $46 | $393 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
23 | $1 | $4 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $105 | $490 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
20 | $1 | $7 |
| New patient office visit, complex (60-74 min) | 18 | $154 | $625 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
15 | $8 | $20 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
15 | $63 | $175 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.4% high complexity
77.0% medium
0.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$165,348
Total received (2018-2024)
Avg $23,621/year across 7 years
Top 5% in IL for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
18
Companies
169
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$111,849 (67.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$51,444 (31.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,054 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$52,576
2023
$49,321
2022
$15,860
2021
$13,680
2020
$20,661
2019
$5,015
2018
$8,234
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SERVIER PHARMACEUTICALS LLC
$20,770
Novocure Inc.
$10,654
Merck Sharp & Dohme LLC
$10,622
Novartis Pharmaceuticals Corporation
$9,134
Telix Pharmaceuticals
$1,165
Boston Scientific Corporation
$124
Gilead Sciences, Inc.
$108
Top 3 companies account for 80.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novocure Inc.
$74,708
Merck Sharp & Dohme LLC
$34,895
SERVIER PHARMACEUTICALS LLC
$24,850
Novartis Pharmaceuticals Corporation
$9,201
AbbVie, Inc.
$7,045
Biogen, Inc.
$3,050
Monteris Medical Corporation
$2,235
Merck Sharp & Dohme Corporation
$2,109
AstraZeneca Pharmaceuticals LP
$1,712
Eisai Inc.
$1,440
F. Hoffmann-La Roche AG
$1,424
Telix Pharmaceuticals
$1,165
Bayer Healthcare Pharmaceuticals Inc.
$940
Celularity Inc.
$289
Boston Scientific Corporation
$124
Gilead Sciences, Inc.
$108
GT Medical Technologies, Inc
$27
Bayer HealthCare Pharmaceuticals Inc.
$27
Top 3 companies account for 81.3% of all-time payments
Associated products mentioned in payments ›
GAMMATILE · ILLUCCIX · IMFINZI · MEKINIST · Neuroblate · Oncology · Optune · TAFINLAR · TECENTRIQ · Tibsovo · Trodelvy · Vitrakvi · Voranigo · WELIREG
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (68%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for neurology in IL.
Geographic Context
Neurologists within 10 mi
585
Per 100K population
11.3
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lukas is a mixed practice specialist, with above-average Medicare volume (top 0% in IL), with speaking/promotional industry engagement in the top 5% of IL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lukas experienced with daratumumab injection (darzalex)?
Based on Medicare claims data, Dr. Lukas performed 13,320 daratumumab injection (darzalex) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lukas receive payments from pharmaceutical companies?
Yes. Dr. Lukas received a total of $165,348 from 18 companies across 169 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lukas's costs compare to other neurologists in Chicago?
Dr. Lukas's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lukas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Chicago
Browse neurologists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in IL
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in IL
Which IL neurologists receive the most from drug and device companies.
By company
Novocure Inc. Payments to Doctors
See all physicians who received payments from Novocure Inc.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
SERVIER PHARMACEUTICALS LLC Payments to Doctors
See all physicians who received payments from SERVIER PHARMACEUTICALS LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology